Teladoc Health director David Snow to retire

Teladoc Health, Inc. reported a planned board change.

Rhea-AI Filing Summary

Teladoc Health, Inc. reported a planned board change. On August 10, 2026, director David B. Snow, Jr. informed the company of his intention to retire from its Board of Directors, effective September 30, 2026. He has served as a director since 2014.

The company states that Mr. Snow is retiring for personal reasons and that his decision is not due to any disagreement with the company on any matter. Teladoc expressed its appreciation for his dedicated service.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Retirement effective date: September 30, 2026 Retirement notice date: August 10, 2026 Board service start year: 2014

3 metrics

Retirement effective date September 30, 2026 Effective date of David B. Snow, Jr.’s retirement from the Board

Retirement notice date August 10, 2026 Date Mr. Snow notified Teladoc Health of his intention to retire

Board service start year 2014 Year David B. Snow, Jr. began serving as a director

Key Terms

Emerging growth company, pre-commencement communications, Securities registered pursuant to Section 12(b)

3 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

pre-commencement communications regulatory

"Pre-commencement communications pursuant to Rule 14d-2(b)"

Securities registered pursuant to Section 12(b) regulatory

"Securities registered pursuant to Section 12(b) of the Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Teladoc Health (TDOC) announce on August 10, 2026?

Teladoc Health announced that director David B. Snow, Jr. plans to retire from its Board, effective September 30, 2026. He has served on the Board since 2014, and the company expressed thanks for his service.

When will Teladoc Health (TDOC) director David B. Snow, Jr. retire from the Board?

David B. Snow, Jr. will retire from the Teladoc Health Board effective September 30, 2026. He notified the company of his intention to retire on August 10, 2026, allowing for a transition period.

Why is Teladoc Health (TDOC) director David B. Snow, Jr. retiring?

David B. Snow, Jr. is retiring from Teladoc Health’s Board for personal reasons. The company reports that his decision is not due to any disagreement with Teladoc on any matter.

How long has David B. Snow, Jr. served on the Teladoc Health (TDOC) Board?

David B. Snow, Jr. has served as a director of Teladoc Health since 2014. His retirement effective September 30, 2026 concludes more than a decade of board service to the company.

Does Teladoc Health (TDOC) report any dispute related to David B. Snow, Jr.’s retirement?

Teladoc Health states that David B. Snow, Jr. is retiring for personal reasons and not because of any disagreement with the company. The disclosure explicitly notes the absence of any such disagreement.

Who signed the Teladoc Health (TDOC) report about the director’s retirement?

The report regarding David B. Snow, Jr.’s retirement was signed by Adam C. Vandervoort, Teladoc Health’s Chief Legal Officer and Secretary, dated August 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2026 - 04:05 PM EDT Learn about SEC filing dates

FALSE0001477449155 E 44th StreetSuite 1700New YorkNY1001700014774492026-08-102026-08-100001477449dei:FormerAddressMember2026-08-102026-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 10, 2026

___________________________________

Teladoc Health, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation)			001-37477 (Commission File Number)			04-3705970 (I.R.S. Employer Identification No.)
155 E 44th Street Suite 1700 New York, NY 10017
(Address of principal executive offices and zip code)
(203) 635-2002
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol			Name of each exchange on which registered
Common stock, par value $0.001 per share			TDOC			The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 10, 2026, Mr. David B. Snow, Jr. notified Teladoc Health, Inc. (the “Company”) of his intention to retire from the Board effective as of September 30, 2026. Mr. Snow has been a director of the Company since 2014 and the Company thanks him for his dedicated service. Mr. Snow has indicated that he is retiring from the Board for personal reasons and not because of any disagreement with the Company on any matter.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 13, 2026

Teladoc Health, Inc.
By:			/s/ Adam C. Vandervoort
Name:			Adam C. Vandervoort
Title:			Chief Legal Officer and Secretary

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.0 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 26.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 15.7 KB